Adjuvant Global Health Technology Fund, L.P., 10% Owner at AN2 Therapeutics, Inc. (ANTX), sold 208,644 shares at $16.07 ($3.4M) on 2023-10-02, disclosed to the SEC on 2023-10-03.
Scheduled sale ($3.4M) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.28 | 15,764 | $257K | 7.6% |
| 2 | $16.28 | 15,764 | $257K | 7.6% |
| 3 | $16.28 | 83,337 | $1.4M | 40.0% |
| 4 | $16.28 | 83,337 | $1.4M | 40.0% |
| 5 | $16.07 | 902 | $14K | 0.4% |
| 6 | $16.07 | 4,770 |
| $77K |
| 2.3% |
| 7 | $16.07 | 4,770 | $77K | 2.3% |
| Total | $16.27 avg | 208,644 | $3.4M | 100% |
| Filing → |